Received Jan 23, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| VARZOS | ZOSTER (SHINGRIX) | GLAXOSMITHKLINE BIOLOGICALS | 2 | 23E4B | — |
received only the liquid (adjuvant) of the Shingrix vaccine; received only the liquid (adjuvant) of the Shingrix vaccine; This non-serious case was reported by a other health professional via call center representative and described the occurrence of inappropriate preparation of medication in a 58-year-old female patient who received Herpes zoster (Shingrix) (batch number 23E4B, expiry date 05-JUN-2027) for prophylaxis. Previously administered products included Shingrix (received 1st dose of vaccine in AUG-2025). On 15-DEC-2025, the patient received the 2nd dose of Shingrix. On 15-DEC-2025, an unknown time after receiving Shingrix, the patient experienced inappropriate preparation of medication (Verbatim: received only the liquid (adjuvant) of the Shingrix vaccine) and inappropriate dose of vaccine administered (Verbatim: received only the liquid (adjuvant) of the Shingrix vaccine). The outcome of the inappropriate preparation of medication and inappropriate dose of vaccine administered were not applicable. Additional Information: GSK Receipt Date: 22-JAN-2026 The physician practice manager had called to report that one of two patients had received only the liquid (adjuvant) portion of the Shingrix vaccine and stated that they were not sure which patient had received only the liquid portion, noting that both patients had been vaccinated on 15-DEC-2025, and asking how long they had to administer a full dose, with the additional clarification that patient number two had previously received a first dose in AUG-2025.; Sender's Comments: US-GSK-US2026010941:SAME REPORTER